⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22565072 | 0.96 | CYP3A4 (0.31) | — | |
| SCHEMBL24697413 | 0.89 | ALDH1A1 (0.35) | — | |
| SCHEMBL24697464 | 0.89 | ALDH1A1 (0.35) | — | |
| SCHEMBL24185424 | 0.88 | HRH3 (0.34) | — | |
| SCHEMBL24480849 | 0.87 | ALDH1A1 (0.36) | — | |
| SCHEMBL24185673 | 0.86 | HRH3 (0.33) | — | |
| SCHEMBL24918142 | 0.85 | — | — | |
| SCHEMBL22565987 | 0.84 | CYP3A4 (0.36) | — | |
| SCHEMBL26743370 | 0.84 | HRH3 (0.33) | — | |
| SCHEMBL24185458 | 0.84 | HRH3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2022253250-A1 | BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING | 正大天晴药业集团股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022111526-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-02 | — | — | WO | disclosed |